Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Hsieh

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
NPJ Parkinson'S Disease|February 28, 2023
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohortsKalpana M Merchant, Tanya Simuni, Janel Fedler, et al.
NPJ Parkinson'S Disease|April 4, 2023
Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson's diseaseSara Gomes, Alicia Garrido, Francesca Tonelli, et al.
JACC. Cardiovascular Imaging|December 3, 2014
FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activityJoshua Lehrer-Graiwer, Parmanand Singh, Amr Abdelbaky, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
NPJ Parkinson'S Disease|February 28, 2023
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohortsKalpana M Merchant, Tanya Simuni, Janel Fedler, et al.
NPJ Parkinson'S Disease|April 4, 2023
Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson's diseaseSara Gomes, Alicia Garrido, Francesca Tonelli, et al.
JACC. Cardiovascular Imaging|December 3, 2014
FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activityJoshua Lehrer-Graiwer, Parmanand Singh, Amr Abdelbaky, et al.
Pageof 6